

Capital Markets Day 2022

22 November 2022

AGENDA

- 1. Dermapharm Group
- 2. Marketing approach
- 3. Allergopharma
- 4. Euromed
- 5. Financials





1 Dermapharm Group - Dr. Hans-Georg Feldmeier, CEO

Image: Günther Fotodesign



1.1 Who we are?

Image: Günther Fotodesign

Dermapharm Group

Our experienced and competent management team





Chief Executive Officer

19 years company affiliation







Karin Samusch

Chief Business Development Officer

31 years company affiliation

Dorsch GmbH



Dr. Andreas Eberhorn

Chief Marketing Officer

as of 1 Sep 2022

SANDOZ A Novartis





Christof Dreibholz

Chief Financial Officer Chief Compliance Officer

as of 1 Nov 2022



Made in Germany, headquartered in Bavaria Boarding completed!



Dermapharm

Dermapharm at a glance

highly attractive and profitable product portfolio


Branded pharmaceuticals

Parallel import business

Herbal extracts

and other healthcare products

... with focus on selected therapeutic areas¹




Allergology

Pain & Inflammation

Cardiovascular Support

Gynaecology & Urology





1 excluding international revenues and vaccine production, based on FY 2021 | 2 EBITDA Margin adjusted for non-recurring costs.




1.2 Where we are today?

Image: Günther Fotodesign

mibe GmbH Arzneimittel

Milestones






Pharmaceutical Excellence


all under one roof with > 700 employees¹





Personnel distribution





R&D philosophy

with a highly efficient development process





Highly efficient and integrated pharmaceutical development process (illustrative)

DEVELOPMENT			CLINICAL STUDY			REGULATORY APPROVAL	
API sourcing	Formu- lation	Analytics Pilot/ Production scale	Non interventional/ Biowaiver	Bioequi- valence	Therapeutic equivalence	Close collaboration with regulatory affairs	
12 – 36 month			0 – 36 month			18 – 36 month	
€ 200 – 600 k			€ 100 – 1,500 k			€ 30 – 50 k per country	

mibe GmbH Arzneimittel Range of dosage forms



Solid forms



- Powders
- Tablets
- Film coated tablets
- Hard gelatin capsules

Liquids/Ointments



- Ointments
- Gels
- Creams
- Lotions
- Liquides

Sterile forms



- Solution for injections
- Freeze dried products
- Eye drops / ointments

mibe GmbH Arzneimittel Range of packaging forms










Sterile Forms



- Blisters
- Tablet container
- Sticks
- Bottles with various dosages, e.g. pipette, spray, dropper
- Tubes
- Sticks
- Ampoules
- Vials
- Ready to fill syringes

mibe GmbH Arzneimittel


Production quantities 2021





Increasing productivity through standards and performance control





mibe GmbH Arzneimittel

Quality assurance / -control



Quality assurance

- QM-Systems
- Compliance
- Qualification / validation
- Documentation
- Quality issues

Quality control

- Chromathography
- Methods of pharmacopoeia
- Special methods
- Microbiological lab





- Testing of active ingredients and other raw materials according to European Pharmacopoeia
- Testing packaging materials according to own specification and testing methods
- Investigation of bulk and manufactured goods
- Stability testing of manufactured goods, bulk and pharmaceutical active ingredients in accordance with ICH-Guideline¹
- Test of sterility







mibe GmbH Arzneimittel

Warehouse and distribution









~ 27,000 Pallet spaces

6,000 m²

Consignment spaces

1,500
Shipped parcels per day
+
~ 45

Shipped pallets per day


~ 24h
Pharmacies & hospitals supply time

~ 48h

wholesalers supply time

90% of product portfolio "made in Germany"


with production of >60m total packs, shipped via central logistic hub in Brehna



Dermapharm

mibe GmbH Arzneimittel – part of solution to the COVID-19 pandemic Step into vaccine production in 2020





Rising energy prices as a result of the Ukraine crisis

Dermapharm

partly mitigated sustainable reduction in energy consumption at the our production sites



Roof top in Brehna

- Commissioned 15 May 2021
- Saving 10% of the electricity consumption
- Planned expansion of solar capacity threefold

Roof Top in Alsdorf

Planned investment in November 2022



Cooling/heating plant in Brehna

Planned in 2024



- Cooling use of a high-efficiency machine and thus reduction of primary energy consumption by 50%, approx. 150,000 KWh
- Heating use of a heat pump for dynamic heating, reduction of primary energy by 66%, approx. 600,000 KWh



1.3 What happened so far in 2022?

Mitigating the COVID-19-pandemic

Impact on our business modell with unexpected growth potential in 2021/2022

Safe working environment



Effective protection concepts at all sites



Vaccination offer to our employees



Field service restrictions



Less presence & home office option



Increasing digitalisation

Production



No lockdown in critical infrastructure



Continuous production despite critical supply chains



24/5 at key production sites As of Q1 2022: Fill & Finish & for shipment

Vaccine production at two sites in Germany

Dermapharm



Integration of AB Cernelle

the founder and leader of extracting pollen for medical use

Development of herbal medicines from high-quality pollen extracts and of the API Cernitin[™]







Pollen

API Cernitin[™]

Cernitol[®]Novum

Synergy effects

- Access to the important active ingredient of Strathmann product "Pollstimol"
- Development of further distribution channels in Asia and Europe



- A pharmaceutical company with research, development and manufacture of drugs in urology, with a special focus on benign prostate enlargement and chronic prostatitis.
- Cernelle with a long tradition of innovative product development
- Cernelle sells the medicines under the brand names Ceritin[™], Cernilton[®], Cernitol[®] and Cernitol[®]Novum through external distributors in Asia and Europe
- Cernilton[®] is one of only two medicines approved worldwide for the effective treatment of chronic prostatitis as well as chronic pelvic pain
- In the wake of an increasing ageing population, these therapeutics offer solid growth potential
- Expected sales revenues 2022: high single digit million Euro range

Dermaphar

Acquisition of C³ Cannabinoid Compound Company



an investment in medical cannabis



... manufactures & ... commercialises natural and synthetic

cannabinoid-based

Active Pharmaceutical Ingredients (API)

- Product portfolio comprises natural and synthetic dronabinol (API) and CBD
- Pioneer for dronabinol in Germany with leading positions also in Austria, Switzerland and Denmark
- Key therapeutic areas: pain and palliative treatment, oncology and neurology, addressing a broad spectrum of chronic and severe illnesses

Spectrum Therapeutics GmbH



Production & sales of natural dronabinol Isolation of GMP-compliant pharmaceutical quality dronabinol from cannabis flower

			-	-
 Τ	Ι	Τ	-	-

Neumarkt

THC Pharm GmbH The Health Concept



Production & sales of synthetic dronabinol Synthesis of dronabinol and CBD in GMP-

compliant pharmaceutical quality with

high-tech chemical processes

 Ħ	-	-
 Т	-	-

Frankfurt

Spectrum Therapeutics Austria GmbH



Sales office



Goodwill-Impairment of fitvia

Lessons learned from influencer marketing



Leading European digital brand for healthy & functional nutrition with a strong sales platform via social media & influencer marketing



Business model has not proven sustainable



Expected synergies to other OTC's and medical devices could not be realised



Discount campaigns did not meet target group's demand, high dependence on special campaigns led to price decline



Significant higher cost for influencer increase of consumer price awareness

Commitment to acquire Arkopharma

a leading producer for food supplements in Western / Southern Europe



Food supplements "made in France" headquartered in Carros close to Nice ArkoPHARMA 1 iconig umbrella brand

>€200m Net Sales 2022e

41% International sales

>20% EBITDA margin

>5% Annual growth

#1 Player in Fance¹

#2 Player in Spain¹ Fully integrated platform with a unique expertise in plant sourcing, manufacturing and natural product developments



Dermapharm



1.4 Introduction to Arkopharma – Dr. Andreas Eberhorn, CMO

Arkopharma at a glance

Leading producer for food supplements in Western / Southern Europe





Food supplements "made in France" headquartered in

Carros close to Nice

ArkoPHARMA 1 iconic umbrella brand

> 200 Mio. € Net Sales 2022e

41% International sales

> 20% EBITDA margin 2022e

> **5%** Annual growth (2020-22e)

#1 Player in Fance¹

#2 Player in Spain¹ Fully integrated platform with a unique expertise in plant sourcing, manufacturing and natural product developments



Strong brand positioning

with significant awareness with the consumer



#1 Most bought OTC brand by 1 in 10 French consumers

#1 Arkopharma vs. strategic sub-brand awareness

#1 Preferred brand Strong loyal consumer base built over the years



Diversified portfolio

built around three main segments...



Phytotherapy	Natural Health	Natural Beauty		
Phytotherapy is Arkopharma's historical core business	Over the years, Arkopharma has diversified its portfolio with natural dietary supplements dedicated to health issues	Similarly, the Group diversified its portfolio with natural dietary supplements dedicated to beauty issues		
 Arkogélules / Arkofluide 	 Azinc / Arkovital Arkorelax Arkoroyal Cys-Control 	 Forcapil 		
	Chrondro Aid ARKOROYAL* ARKORELAX* CYS-CONTROL* CHONDRO-AID*			

Arkopharma sales by therapeutic areas


...with 7 strategic sub-brands, representing ~80% of sales




>€200m			CAGR 2019–2022e	
20%	7 Joint	CHONDRO-AID®	+7.7%	Become the reference brand for all health issues related to joints
5% 6%	6 Urinary	CYS-CONTROL	+5.5%	Roll-out in key geographies through a physician driven model
6% 7%	5 Immunity	ARKOR @ YAL°	+0.7%	Strengthen positioning by better communicating its uniqueness
11%	4 Sleep & Stress	ARKO RELAX *	+30.0%	Focus on innovation by leveraging on CBD launch
14%	3 Fatigue & Ener	gy AZINC ARKOVITAL®	+20.9%	Upgrade formulas and become reference brand for all markets
31%	2 Hair & Beauty	FORCAPIL	+32.4%	Focus on innovation and product extensions into adjacent segment
Net sales 2022e	1 Phytotherapy	Arkogélules / Arkofluides	+1.1% +4.8%	Boost growth in combined phytotherapy products through innovative product launches

Arkopharma with a large European footprint







Sources Company information, Deloitte

1 Including 950 Bio stores for France (400 POS) & Netherlands (550 POS) and excluding wholesalers for all markets | 2 Includes DOM-TOM 3 Others include Switzerland and Netherlands

Further internationalisation

... and use of product synergies



Keltica

0

Tromcardin'

Capital Markets Day 2022

34

Trommsdo

Dekristol 1000

Dekristol" 20 000 LE.

mibe

mibe GmbH Arzneimittel

50 Weichkapper

Eisen







2 Marketing approach – Dr. Andreas Eberhorn, CMO

Highly effective sales organisation and strategy

securing customer access and highest number of prescriptions



173,770

158,865

122,455

36.062




1 Kassenärztliche Bundesvereinigung, ABDA, internal data | All figures refer to Germany as of June 2022;

1 Pharmaceutical firms selling over 50,000 units per year in Germany, sell out data IH-Galaxy Apo Fusion insight health - MAT Jun 2022 in tsd. Units.

Leading branded pharmaceuticals manufacturer



in selected therapeutic areas



Leading branded pharmaceuticals manufacturer



in selected therapeutic areas (1/2)



Source: Company information, Individual market definition by Dermapharm on the basis of Insight Health data – ApoFusion, sell out data 1 Market position: Market definitions include molecules and ATC-markets of Dermapharm portfolio, RX, OTC and health products and include competitors with more than €75.000k yearly revenue in the respective market | Market (share) growth based on molecules and ATC-markets of Dermapharm portfolio, RX, OTC and health products set for the respective market | Market (share) growth based on molecules and ATC-markets of Dermapharm portfolio, RX, OTC and health products, ex factory prices. 1 Gross sales in the segment "Branded pharmaceuticals and other healthcare products" in Germany.



Leading branded pharmaceuticals manufacturer



in selected therapeutic areas (2/2)




of 63



Source: Company information, Individual market definition by Dermapharm on the basis of Insight Health data – ApoFusion, sell out data 1 Market position: Market definitions include molecules and ATC-markets of Dermapharm portfolio, Rx, OTC and health products and include competitors with more than €75.000k yearly revenue in the respective market | Market (share) growth based on molecules and ATC-markets of Dermapharm portfolio, Rx, OTC and health products, ex factory prices. 1 Gross sales in the segment "Branded pharmaceuticals and other healthcare products" in Germany.

Dermapharm Group Product Split





Our growth categories

equally represented by Rx and OTC priority products








Dermapharm **Growth Driver Market Leadership** Tromcardin complex **No.1 No.1** Based on Dekristol 20000LE sales growth Based on Weichkapseln Colecalciferol (Vitamin D.) Dekristol[®] 1000 rate brand sales Colecalciferol (Vitamin D₃) Zur Anwendung bei Säuglingen, Jugendlichen und Erwachsenen **Keltican**[°] Myditin® nd Folsäure zum Diätmanagerne Tromcardin 8 complex **Unique Products** Hygroton[®] 50 mg Langzeitdiaretikum un Antihypertetränum 8 100 Tables Vaginal **Gvnatren*** mycosis tionssuspension stoff: Inaktivierte Keime erter Lactobacillus-Stäm STRATHN Chronic ----**Pelvic Pain** Urinary tract Syndrome StroVac* Pollstimol* infections

Highlights from our key strategic markets

Overview of sell-out performance

Dermapharm

of our priority products






Calcipotriderm Comp. Gel Successful launch after patent expiry (10'21)



Today # 2 in market thanks to fast market entry driven by made in Germany






Keltican forte defends brand revenues



in decreasing, saturated market resulting in market share expansion





StroVac has high untapped potential



among unaware sufferers and additional growth potential via StroVac booster



Disclaimer



This publication includes statements, estimates, opinions and projections with respect to the anticipated future performance of Dermapharm Holding SE (together with its consolidated subsidiaries, "Dermapharm") and such statements, estimates, opinions and projections ("Forward-Looking Statements") reflect various assumptions concerning anticipated results based on Dermapharm's current business plan or publicly available sources which have not been independently verified or assessed by Dermapharm and which may prove to be incorrect.

The Forward-Looking Statements reflect current expectations based on the current business plan and various other assumptions, involve significant risks and uncertainties, should not be read as a guarantee of future performance or results and may not necessarily be accurate indications of whether or not such results will be achieved. The Forward-Looking Statements only speak as of the date of this publication. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of Dermapharm and the estimates given herein. These factors include those discussed in Dermapharm's financial statements which are available on Dermapharm's website. Each recipient of this publication should make its own assessment of the validity of Forward-Looking Statements and other assumptions and, Dermapharm accepts no liability with respect to any Forward-Looking Statements or other assumptions.

Except as provided by law, Dermapharm assumes no obligation whatsoever to update or revise any of the information, Forward-Looking Statements and conclusions contained herein, or to reflect new events or circumstances or to correct any inaccuracies which may become apparent subsequent to the date hereof.

For information, please contact

Britta Hamberger Investor Relations & Corporate Communications Dermapharm Holding SE

E-Mail: ir@dermapharm.com Phone: +49 (0) 89 641 86 233